At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1 enrolled
Drug / intervention
NOVOTTF-200Adevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II, Single Arm Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent WHO Grade III Malignant Astrocytoma
In Brief
A clinical study evaluating NOVOTTF-200A for Astrocytoma, Grade III. Completed, enrolled 1 participant across 1 site.
Detailed Summary
This is a Phase 2 study in subjects with WHO Grade III Anaplastic Astrocytoma (G3 astrocytoma) who had progressive disease during first or second line treatment and who have not previously received any BEV or any experimental agents.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAstrocytoma, Grade III
CountriesUnited States
CollaboratorsNovoCure Ltd.
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
First PostedMar 2018
Enrollment StartMay 2020
Primary CompletionSep 2023
Study CompletionAug 2025
TodayJul 2026
First PostedMar 1, 2018
Enrollment StartMay 21, 2020
Primary CompletionSep 7, 2023
Study CompletionAug 7, 2025
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 8.3 years ago
Interventions
NOVOTTF-200Adevice
NOVOTTF-200A will be administered under appropriate guidelines. Monthly adherence rate \>= 75% (\>= 18 hours/day) over a 4-week cycle (28 days) will be strongly encouraged.